FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379281419> ?p ?o ?g. }

• W4379281419 endingPage "e20568" @default.
• W4379281419 startingPage "e20568" @default.
• W4379281419 abstract "e20568 Background: Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare lung cancer subtype. Despite advances in understanding lung cancer biology, a consensus on the use of consolidation immunotherapy (IO) in patients with LCNEC is still lacking. Methods: Using National Cancer Database (NCDB), we reviewed stage III lung LCNEC cases diagnosed from 2017 through 2019 with a follow-up through 2020. Several variables were incorporated into the multivariate logistic regression analysis, including age, gender, race, Charlson-Deyo comorbidity score (CDCS), insurance status, and IO use. Survival distribution was examined using the Kaplan-Meier analysis and compared by the log-rank test. Results: A total of 956 cases with a male:female ratio of 1.2:1, and a median age (±SD, range) of 66.4 (±9.7, 37–90) years—baseline characteristics are shown in the Table. In the univariate analysis, IO use (n = 184) resulted in a superior median overall survival (mOS; 30.6 vs. 20.3 months, HR 0.76, 95% CI 0.62-0.96, p = 0.02, compared to no IO use). Results from multivariate analysis further demonstrated survival benefit with IO use (HR 0.79, 95% CI 0.63-0.98, p = 0.03, compared to no IO use). Additionally, in the multivariate analysis, the female gender was associated with improved survival (HR 0.84, 95% CI 0.71-0.99, p = 0.04); while notable factors associated with reduced survival were age ≥75 years (HR 1.45, 95% CI 1.08-1.95, p = 0.01, compared to 18-64 years age group), CDCS of ≥1 (HR 1.19, 95% CI 1.004-1.420, p = 0.04, compared to zero), and Medicaid (HR 1.46, 95% CI 1.05-2.05, p = 0.02, compared to private insurance). There was no statistical significance for OS noted with age group 65-74 years (HR 1.09, 95% CI 0.84-1.42, p = 0.49, compared to 18-64 years age group); and race (African American, HR 1.001, 95% CI 0.77-1.29, P = 0.99, compared to White). Conclusions: This study shows that IO improves survival in stage III LCNEC. Despite the inherent limitations of the database, our findings are intriguing and warrant further evaluation through prospective clinical trials in order to assess and optimize the benefit of IO in this patient population. [Table: see text]" @default.
• W4379281419 created "2023-06-05" @default.
• W4379281419 creator A5062197967 @default.
• W4379281419 creator A5065913769 @default.
• W4379281419 creator A5076407661 @default.
• W4379281419 date "2023-06-01" @default.
• W4379281419 modified "2023-09-25" @default.
• W4379281419 title "The role of immunotherapy in stage III large cell neuroendocrine carcinoma of the lung (LCNEC): A retrospective NCDB analysis." @default.
• W4379281419 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e20568" @default.
• W4379281419 hasPublicationYear "2023" @default.
• W4379281419 type Work @default.
• W4379281419 citedByCount "0" @default.
• W4379281419 crossrefType "journal-article" @default.
• W4379281419 hasAuthorship W4379281419A5062197967 @default.
• W4379281419 hasAuthorship W4379281419A5065913769 @default.
• W4379281419 hasAuthorship W4379281419A5076407661 @default.
• W4379281419 hasConcept C10515644 @default.
• W4379281419 hasConcept C126322002 @default.
• W4379281419 hasConcept C143998085 @default.
• W4379281419 hasConcept C144301174 @default.
• W4379281419 hasConcept C146357865 @default.
• W4379281419 hasConcept C151730666 @default.
• W4379281419 hasConcept C2776256026 @default.
• W4379281419 hasConcept C38180746 @default.
• W4379281419 hasConcept C71924100 @default.
• W4379281419 hasConcept C86803240 @default.
• W4379281419 hasConceptScore W4379281419C10515644 @default.
• W4379281419 hasConceptScore W4379281419C126322002 @default.
• W4379281419 hasConceptScore W4379281419C143998085 @default.
• W4379281419 hasConceptScore W4379281419C144301174 @default.
• W4379281419 hasConceptScore W4379281419C146357865 @default.
• W4379281419 hasConceptScore W4379281419C151730666 @default.
• W4379281419 hasConceptScore W4379281419C2776256026 @default.
• W4379281419 hasConceptScore W4379281419C38180746 @default.
• W4379281419 hasConceptScore W4379281419C71924100 @default.
• W4379281419 hasConceptScore W4379281419C86803240 @default.
• W4379281419 hasIssue "16_suppl" @default.
• W4379281419 hasLocation W43792814191 @default.
• W4379281419 hasOpenAccess W4379281419 @default.
• W4379281419 hasPrimaryLocation W43792814191 @default.
• W4379281419 hasRelatedWork W1863259896 @default.
• W4379281419 hasRelatedWork W1985349485 @default.
• W4379281419 hasRelatedWork W2163263812 @default.
• W4379281419 hasRelatedWork W2357428483 @default.
• W4379281419 hasRelatedWork W2361700749 @default.
• W4379281419 hasRelatedWork W2367054191 @default.
• W4379281419 hasRelatedWork W2411442805 @default.
• W4379281419 hasRelatedWork W3140385248 @default.
• W4379281419 hasRelatedWork W3159490203 @default.
• W4379281419 hasRelatedWork W3185622540 @default.
• W4379281419 hasVolume "41" @default.
• W4379281419 isParatext "false" @default.
• W4379281419 isRetracted "false" @default.
• W4379281419 workType "article" @default.